Table 3 Distribution of alleles and genotypes for PNPLA3 rs738409 and TM6SF2 rs58542926 polymorphisms and association tests considering significant hepatic fibrosis
PNPLA3 rs738409 and TM6SF2 rs58542926 genotypes/alleles | Frequency in CHC patients n (%) | |
|---|---|---|
Fibrosis grade F0-F1 (n = 278) | Fibrosis grade ≥ F2 (n = 218) | |
PNPLA3 | ||
CC | 176 (63.3%) | 127 (58.3%) |
CG | 86 (30.9%) | 74 (33.9%) |
GG | 16 (5.8%) | 17 (7.8%) |
C | 438 (79%) | 328 (75%) |
G | 118 (21%) | 108 (25%) |
TM6SF2 | ||
CC | 239 (86%) | 189 (86.7%) |
CT | 37 (13.3%) | 27 (12.4%) |
TT | 02 (0.7%) | 02 (0.9%) |
C | 515 (93%) | 405 (93%) |
T | 41 (07%) | 31 (07%) |
OR statistics | OR (95% CI) | p-value |
PNPLA3 | ||
CC vs GG (genotypic model) | 1.47 (0.72–3.02) | 0.45 |
CC vs CG-GG (dominant model) | 1.24 (0.86–1.78) | 0.25 |
CC-CG vs GG (recessive model) | 1.38 (0.68–2.81) | 0.37 |
C vs G (allelic model) | 1.22 (0.91–1.65) | 0.21 |
TM6SF2 | ||
CC vs TT (genotypic model) | 1.26 (0.18–9.06) | 0.93 |
CC vs CT-TT (dominant model) | 0.94 (0.56–1.58) | 0.82 |
CC-CT vs TT (recessive model) | 1.28 (0.18–9.14) | 0.81 |
C vs T (allelic model) | 0.96 (0.59–1.56) | 1.0 |